Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Amortization of Deferred Charges: 2019-2020

  • Avidity Biosciences' Amortization of Deferred Charges was N/A to $20,000 in Q2 2020 from the same period last year, while for Jun 2020 it was $70,000, marking a year-over-year change of. This contributed to the annual value of $29,000 for FY2020, which is 59.15% down from last year.
  • Per Avidity Biosciences' latest filing, its Amortization of Deferred Charges stood at $20,000 for Q2 2020, which was up 122.22% from $9,000 recorded in Q1 2020.
  • Over the past 5 years, Avidity Biosciences' Amortization of Deferred Charges peaked at $27,000 during Q3 2019, and registered a low of $9,000 during Q1 2020.
  • Moreover, its 2-year median value for Amortization of Deferred Charges was $17,000 (2019), whereas its average is $17,500.